Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.
2 reports, 1 independent
Updated Jul 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada raised its price objective on Sarepta Therapeutics, which is listed on Nasdaq, with MarketBeat providing average ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sarepta Therapeutics
biopharmaceutical company
Nothing else this week.
-
Royal Bank of Canada
financial institution in Canada
-
MarketBeat
American personal finance blog
Related events
- Jefferies Financial Group reaffirmed a 'buy' rating and issued a $45.00 target price for NewAmsterdam Pharma, Inc.
- Benzinga reported on Costco's price target changes, while Royal Bank of Canada issued a sector performance rating and MarketBeat provided consensus data.
- MarketBeat reports average rating and target price for SS&C Technologies, while RBC boosts targets and Jefferies reduces its price objective.
- Analyst raised price target and gave outperform rating for Aramark on August 19, 2026.
- Financial firms including Royal Bank of Canada, Truist Financial, TD Cowen, and Barclays have announced price target increases for Medpace.